Title:
DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
Document Type and Number:
WIPO Patent Application WO/2022/012623
Kind Code:
A1
Abstract:
Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
Inventors:
LEI BAILIN (CN)
LIU HUAQING (CN)
HAN SONGZHE (CN)
WANG ZHIWEI (CN)
LIU HUAQING (CN)
HAN SONGZHE (CN)
WANG ZHIWEI (CN)
Application Number:
PCT/CN2021/106485
Publication Date:
January 20, 2022
Filing Date:
July 15, 2021
Export Citation:
Assignee:
BEIGENE LTD (GB)
LEI BAILIN (CN)
LEI BAILIN (CN)
International Classes:
C07D401/12; A61K31/4015; A61K31/403; A61K31/495; A61K31/496; A61K31/4965; A61K31/497; A61P35/00; C07D401/02; C07D401/14; C07D471/00; C07D487/00; C07F9/02; C07F9/50; C07F9/53
Domestic Patent References:
| WO2021036922A1 | 2021-03-04 | |||
| WO2020113233A1 | 2020-06-04 | |||
| WO2019015655A1 | 2019-01-24 | |||
| WO2019060742A1 | 2019-03-28 |
Foreign References:
| CN110357889A | 2019-10-22 | |||
| CN109912655A | 2019-06-21 |
Attorney, Agent or Firm:
WU, FENG & ZHANG (CN)
Download PDF: